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The newly published World Health Organization (WHO) Classification of Tumours of the breast 
features significant changes compared to earlier editions. In this review, we outline the major 
changes in this important reference source for those diagnosing tumours, or engaged in cancer 
research, and describe the significant changes. For breast cancer, the overview acknowledges the 
treatment-relevant subtypes of invasive carcinoma (based on ER and HER2 status) and new data 
is added to support the differences in pathogenesis, treatment response and prognosis of these 
clinically relevant groupings.   The WHO Classification of Tumours is increasingly evidence-based, 
with a clear update cycle, improved quality of illustrations, as well as content, led by an editorial 
board comprising pathologists, but increasingly incorporating input from other disciplines.  The 
advent of the new website allows the use of whole slide images, and hyperlinks to evidence or 




The classification of breast tumours continues to evolve, with the integration of new knowledge 
from research rapidly being translated into clinical practice. Major changes are listed in table 1. 
In this volume of the WHO Classification of Tumours series’ fifth edition, which is an update of 
the fourth-edition breast tumours volume published in 2012,1 the descriptions of breast tumours 
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sequence from benign epithelial proliferations and precursors, through benign neoplasms, to in 
situ and invasive breast cancer, followed by mesenchymal and haematolymphoid neoplasms, 
tumours of the male breast, and genetic tumour syndromes. 
  
A brief introduction prefaces the content pertaining to each major tumour group, to provide a 
general perspective and highlight key modifications. In the current volume, information on 
epidemiology, imaging, clinical features, grading, staging, molecular testing for hormone 
receptors and ERBB2 (HER2), post-therapy effects, core needle biopsy and FNA considerations, 
molecular pathology, and genomics, is now presented in the general overview that introduces 
the sections on invasive breast carcinoma, rather than in the first chapter as in the prior edition. Core 
biopsy diagnosis, an important preoperative tool, is addressed across multiple sections. The 
importance of molecular pathology in aiding diagnosis is recognized, with a specific subsection 
for each tumour type. Essential and desirable diagnostic criteria are also included, to reinforce 





Invasive breast cancers are still organized into chapters by their morphologic subtypes, which 
remain clinically relevant.  However, since the majority of cases are of no special type (NST), 
additional prognostic and predictive factors that aid significantly in treatment and outcome 
stratification are also focused on and reviewed in more depth in the   
invasive carcinoma overview section.  The overview acknowledges the treatment-relevant 
subtypes of invasive carcinoma (based on ER and HER2 status) and new data is added to support 
the differences in pathogenesis, treatment response and prognosis of these clinically relevant 
groupings.   Updates in defining and testing hormone receptor and HER2 status are presented as 
well as updated sections on additional assays and parameters used in prediction and prognosis 
(including proliferation markers, AR, response to neoadjuvant therapy, gene expression assays, 
tumour infiltrating lymphocytes, prognostic scoring systems and PDL1 testing).    The overview 
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data supporting classifications schemes that have prognostic associations (including the intrinsic 
subtypes, integrative cluster subgroups, triple negative sub-classifications, and mutation based 
profiling). 
  
Standard prognostic indicators, such as tumour size, lymph node status and Nottingham grade 
continue to be highly relevant.  An important change in this edition is the conversion of mitotic 
count from the traditional denominator of 10 high-power fields to a defined area expressed in 
mm2. This serves to standardize the true area over which mitoses are enumerated, because 
different microscopes have high-power fields of different sizes. This change will also be helpful 
for anyone reporting using digital systems. The score thresholds for mitotic counts based on the 
diameter of the high-power field and its corresponding area are presented in Table 2. 
  
Updates to the “Invasive breast carcinoma, NST” section include a revised definition of the mixed 
NST-special subtype (now expanded to include cases with 10-90% special subtype admixed with 
NST with recommendation to include parameters about both components). Classification of 
several patterns previously recognized as separate special rare subtypes have moved under the 
NST umbrella as “Special morphologic patterns”.   Carcinomas previously classified as the special 
subtype “carcinoma with medullary features” (including medullary carcinoma, atypical medullary 
carcinoma, and invasive carcinoma of no special type (NST) with medullary features) have 
suffered from poor interobserver reproducibility and overlap in features with carcinomas that 
have basal-like molecular profiles and carcinomas associated with BRCA1 mutations. In addition, 
the increasing affirmation of the prognostic importance of TILs in high-grade breast cancers in 
explaining their good prognosis, including high-grade cancers not meeting strict medullary 
criteria, reduce the requirement for discrete separation of these tumours that exist along a 
morphological continuum.  Therefore, for clinical purposes, it is now proposed to consider 
carcinomas with medullary pattern as representing one end of the spectrum of the TIL-rich IBC-
NSTs rather than a distinct morphological subtype, and to use the term “IBC-NST with medullary 
pattern”.    In addition, oncocytic, lipid-rich, glycogen-rich clear cell, sebaceous carcinomas, which 
are rarely encountered, are also now recognized as special patterns of NST along with carcinoma 
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melanotic patterns.  Inflammatory and bilateral and non-synchronous breast carcinomas are also 
now recognized as distinct clinical presentations rather than special subtypes of breast cancer.   
  
Next to classic lobular carcinoma in situ (LCIS), the pleomorphic and florid subtypes are now 
recognized. Pleomorphic LCIS shows marked nuclear atypia, and may include apocrine features, 
while in florid LCIS, there is marked distention of TDLUs or ducts often forming a mass-like 
appearance. It is now recognized that some invasive lobular carcinomas may be associated with 






Although neuroendocrine neoplasms (NENs) are allocated their own section, harmonized with 
those of other organ systems on the basis of a recent WHO workshop report,2 it must be 
emphasized that true primary neuroendocrine tumours (NETs) of the breast remain uncommon 
and poorly defined. According to the proposed consensus terminology, well differentiated NETs 
broadly correspond to grade 1 (carcinoid-like) and 2 (atypical carcinoid-like) tumours (regarded 
as carcinomas in the breast), while poorly differentiated NECs are typified by small and large cell 
carcinoma.  Many breast tumours that display varying degrees of neuroendocrine differentiation 
belong to recognized entities such as hypercellular mucinous carcinoma and solid papillary 
carcinoma of both in situ and invasive forms. Small cell neuroendocrine carcinoma (SCNEC) does 
arise in the breast, often admixed with invasive carcinoma NST. Large Cell Neuroendocrine 
Carcinoma (LCNEC) has been added as an entity arising in the breast, albeit very rare. For well-
differentiated NETs resembling carcinoid or atypical carcinoid tumour, it is prudent to exclude 
metastasis from another site. It is recommended that the classification of breast tumours 
displaying neuroendocrine expression be based on the recognizable morphological tumour type, 
such as invasive carcinoma NST, mucinous carcinoma, or solid papillary carcinoma.3 Because 
some degree of neuroendocrine expression is relatively common in invasive breast cancer of no 
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invasive carcinoma NST with neuroendocrine differentiation. Only if neuroendocrine histological 
features and neuroendocrine marker expression are distinct or uniform enough to classify a 
cancer as one of the rare NETs or NECs of the breast, should NEN terminology be used.  NET or 
NEC of the breast are currently treated based on standard breast cancer parameters (such as ER 
and HER2 status).  Th new WHO Classification is not advocating routine evaluation for 
neuroendocrine markers in breast cancers. 
  
  
Other tumour types and newly recognized entities 
One important change in the classification of fibroepithelial tumours is the removal of well-
differentiated liposarcoma as a histological criterion of malignancy in breast phyllodes tumours in 
the absence of additional supporting microscopic alterations. Evidence has emerged that these 
abnormal adipocyte populations residing within phyllodes tumours do not harbour 
the MDM2 aberrations that characterize well-differentiated liposarcomas elsewhere. In light of 
the consensus opinion that this heterologous element does not have metastatic potential, it was 
agreed that its presence alone should not warrant a malignant grade in phyllodes tumours unless 
there are other histological changes of malignancy. 
A new entity included in this volume is mucinous cystadenocarcinoma, a unique invasive 
malignancy with relatively good prognosis, featuring luminal mucin and cytomorphology 
resembling pancreatobiliary and ovarian mucinous cystadenocarcinoma. The entity “tall cell 
carcinoma with reversed polarity” is introduced in the section about rare and salivary gland–type 
tumours, as there have been multiple reports of this entity, previously termed “breast tumour 
resembling the tall cell variant of papillary thyroid carcinoma” as well as “solid papillary 
carcinoma with reverse polarity”, with these descriptions united by the consistent finding 
of IDH2 and PIK3CA mutations.4 The new terminology of ‘tall cell carcinoma with reversed 
polarity’ incorporates portions of earlier terms used to describe this entity – ‘tall cell’ and 
‘reversed polarity’.  This revised term was a consensus agreement achieved during the WHO 
Editorial Board Meeting.  It was also felt that having ‘papillary thyroid carcinoma’ in the 
terminology may be confusing and misleading.  Periductal stromal tumour is now considered a 
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Mesenchymal tumours, haematolymphoid tumours, and genetic tumour syndromes are covered 






Tumour classification is a dynamic process, integrating multiple sources of information that have 
emerged since the previous WHO update. Digital pathology, which is becoming widely available, 
may enable the application of new artificial intelligence and computer learning tools to refine 
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Board, or the IARC Secretariat. This commentary is based on the introduction to tumours of the 
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Table 1.  Major changes within the new classification of tumours of the breast.  
 
Topic  Status WHO 2012  Change in WHO 2019  
Mitotic counts  Expressed per 10 HPF  Given per mm2  
Carcinoma with medullary 
features  
Separate entity  Now regarded as TIL-rich 
IBC-NST  
Oncocytic, lipid-rich, 
glycogen-rich clear cell, 
sebaceous, pleomorphic, 
melanotic, oncocytic and 
choriocarcinomatous 
carcinomas, carcinoma 
with osteoclast-like giant 
stromal giant cells  
Separate entities  Now regarded as rare 
variants of carcinoma NST  
Inflammatory, bilateral 
and non-synchronous 
breast carcinomas  
Separate entities  Now recognized as 
distinct clinical 
presentations rather than 
special subtypes  
Lobular carcinoma in situ  Classic, pleomorphic, 
macroacinar, apocrine 
types  
Classic, pleomorphic and 
florid types  
Neuroendocrine 
neoplasms  
   True primary 
neuroendocrine 
neoplasms are typed as 
NET, SCNEC or LCNEC  
Neuroendocrine 
differentiation  
   Overridden by 
morphological tumour 





phyllodes tumours  
Histological criterion of 
malignancy by itself  
No longer a histological 




Not recognized  Recognized as new entity  
Breast tumour resembling 
the tall cell variant of 
papillary thyroid 
carcinoma;  
solid papillary carcinoma 
with reverse polarity  
Similar separately 
mentioned entities  
Now grouped as tall cell 
carcinoma with reversed 
polarity  
Periductal stromal tumour  Separate fibroepithelial 
entity  




tumours, and genetic 
tumour syndromes  
   Covered in dedicated 
chapters  
 
Table 2. Score thresholds for mitotic counts based on the diameter of the high-power 
field and its corresponding area  






Mitotic count (score)  
1  2  3  
0.40  0.126 ≤ 4  5–9  ≥ 10  
0.41  0.132  ≤ 4  5–9  ≥ 10  
0.42  0.138  ≤ 5  6–10  ≥ 11  
0.43  0.145  ≤ 5  6–10  ≥ 11  
0.44  0.152  ≤ 5  6–11  ≥ 12  
0.45  0.159  ≤ 5  6–11  ≥ 12  
0.46  0.166  ≤ 6  7–12  ≥ 13  
0.47  0.173  ≤ 6  7–12  ≥ 13  
0.48  0.181  ≤ 6  7–13  ≥ 14  
0.49  0.188  ≤ 6  7–13  ≥ 14  
0.50  0.196  ≤ 7  8–14  ≥ 15  
0.51  0.204  ≤ 7  8–14  ≥ 15  
0.52  0.212  ≤ 7  8–15  ≥ 16  
0.53  0.221  ≤ 8  9–16 ≥ 17  
0.54  0.229  ≤ 8  9–16  ≥ 17  
0.55  0.237  ≤ 8  9–17  ≥ 18  
0.56  0.246  ≤ 8  9–17  ≥ 18  
0.57  0.255  ≤ 9  10–18  ≥ 19  
0.58  0.264  ≤ 9  10–19  ≥ 20  
0.59  0.273  ≤ 9  10–19  ≥ 20  
0.60  0.283  ≤ 10  11–20  ≥ 21  
0.61  0.292  ≤ 10  11–21  ≥ 22  
0.62  0.302  ≤ 11  12–22  ≥ 23  
0.63  0.312  ≤ 11  12–22  ≥ 23  
0.64  0.322  ≤ 11  12–23  ≥ 24  
0.65  0.332  ≤ 12  13–24  ≥ 25  
0.66  0.342  ≤ 12  13–24  ≥ 25  
0.67  0.352  ≤ 12  13–25  ≥ 26  
0.68  0.363  ≤ 13  14–26  ≥ 27  
0.69  0.374  ≤ 13  14–27  ≥ 28  
   
   
   
